Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Distinct outcome patterns according to RAS and BRAF status in MSI-H/dMMR mCRC treated with immune checkpoint inhibitors: A systematic review and meta-analysis.

Cancer treatment reviews - 1 Sept 2026

Pretta Andrea, Giampieri Riccardo, Bottelli Andrea, Taravella Ada, Intini Rossana, Ziranu Pina, Liguori Carolina, Manoni Federica, Landi Matteo, Maddalena Giulia, Locci Giorgia, Donisi Clelia, Masiello Mariapaola, Caschili Matteo, Bassetti Anna, Pasquinucci Valentino, Maccioni Antonio, Sperotto Sara, Bergamo Francesca, Berardi Rossana, Pietrantonio Filippo, Cremolini Chiara, Lonardi Sara, Scartozzi Mario

Abstract excerpt

BACKGROUND: Immune checkpoint inhibitors (ICIs) are superior to chemotherapy in metastatic colorectal cancer (mCRC) with MSI-H/dMMR. However, whether oncogenic driver alterations contribute to clinically meaningful heterogeneity in outcomes within this immunotherapy-sensitive population remains unclear. We conducted a systematic review and meta-analysis to evaluate the association between RAS and BRAF mutational...

Read the complete abstract on PubMed

Topics

Humans
Colorectal Neoplasms
Immune Checkpoint Inhibitors

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Microsatellite Instability

Mutation

Proto-Oncogene Proteins B-raf

ras Proteins

Source

Identifiers

PMID: 42497817
DOI: 10.1016/j.ctrv.2026.103178

Genes

BRAF

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 21 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Distinct outcome patterns according to RAS and BRAF status in MSI-H/dMMR mCRC treated with immune checkpoint inhibitors: A systematic review and meta-analysis.PMID 42497817Read ↗

BRAF V600E/RAS Mutations and Lynch Syndrome in Patients With MSI-H/dMMR Metastatic Colorectal Cancer Treated With Immune Checkpoint Inhibitors.Semantic proximity Read ↗

Immune checkpoint inhibitors for the treatment of MSI-H/MMR-D colorectal cancer and a perspective on resistance mechanismsSemantic proximity Read ↗

Outcomes of Chemotherapy for Microsatellite Instable–High Metastatic Colorectal CancersSemantic proximity Read ↗

Exploring biological heterogeneity and implications on novel treatment paradigm in BRAF-mutant metastatic colorectal cancer.Semantic proximity Read ↗

Immunotherapy with immune checkpoint inhibitors in colorectal cancer: what is the future beyond deficient mismatch-repair tumours?Semantic proximity Read ↗

Immune-Checkpoint Inhibitors (ICIs) in Metastatic Colorectal Cancer (mCRC) Patients beyond Microsatellite InstabilitySemantic proximity Read ↗

Colorectal cancer with BRAF V600E mutation: Trends in immune checkpoint inhibitor treatment.Semantic proximity Read ↗

First-line Nivolumab plus FOLFOXIRI/Bevacizumab in advanced RAS/BRAF-mutated colorectal cancer: efficacy, safety and biomarker discovery from the phase II NIVACOR trial.Semantic proximity Read ↗

Immunotherapy for the treatment of colorectal cancerSemantic proximity Read ↗

A Narrative Review of the Role of Immunotherapy in Metastatic Carcinoma of the Colon Harboring a BRAF Mutation.Semantic proximity Read ↗

Microsatellite instability-high status as a pan-cancer biomarker for immunotherapy efficacySemantic proximity Read ↗

Effect of RAS mutations and related immune characteristics on the prognosis of patients with MSI-H/dMMR colorectal cancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.